NDV-HXP-S

Last updated

NDV-HXP-S
Butanvac embalagem.jpg
Packaging for the Brazilian version of NDV-HXP-S, ButanVac
Vaccine description
Target SARS-CoV-2
Vaccine type viral vector or inactivated
Clinical data
Trade names ButanVac (Brazil)
COVIVAC (Vietnam)
HXP-GPOVac (Thailand)
Patria (Mexico)
Other namesADAPTCOV
Routes of
administration
Intramuscular, [1] Intranasal

NDV-HXP-S (known as ButanVac [2] [3] or ADAPTCOV [4] in Brazil, COVIVAC [5] in Vietnam, HXP-GPOVac [6] in Thailand, Patria [7] in Mexico) is a COVID-19 vaccine candidate developed by a team led by Jason McLellan at the University of Texas at Austin, [8] together with groups from the Icahn School of Medicine at Mount Sinai and the National Institute of Allergy and Infectious Diseases Vaccine Research Center, based on an improved spike protein central to its resilience and efficacy. [9]

Contents

The name NDV-HXP-S comes from the terms Newcastle disease virus, HexaPro, and spike protein. [10] [ failed verification ]

Pharmacology

NDV-HXP-S uses the Newcastle disease virus as its viral vector or inactivated. [11]

Manufacturing

Unlike vaccines such as Moderna's mRNA-1273, the Janssen vaccine, and Pfizer–BioNTech's tozinameran, which all require both specialized manufacturing facilities and also rare or expensive ingredients, NDV-HXP-S can be produced using chicken eggs in a fashion similar to flu vaccine production, making it especially important to and for middle- and low-income countries. [9] Those existing vaccines are based on the 2P spike, while NDV-HXP-S is further refined via the same process, resulting in a new spike called HexaPro; [12] the 2P spike contained two prolines compared with HexaPro's six. It is also more resistant to heat and chemicals than the original 2P spike; the vaccine can be stored at 2–8 °C. [10]

History

Development

Its development was coordinated by the PATH Center for Vaccine Innovation and Access, and UT Austin and ISMMS have arranged royalty-free licensing agreements with labs and corporations in 80 countries. McLellan has noted that "the share of vaccines ['low- and middle-income countries' have] received so far is terrible". [9]

Clinical trials

Sao Paulo governor Joao Doria displaying Butanvac at a press conference on March 26, 2021. Joao Doria anuncia a Butanvac.jpg
São Paulo governor João Doria displaying Butanvac at a press conference on March 26, 2021.

As of April 2021 NDV-HXP-S is undergoing initial clinical trials in humans in at least four countries. In Brazil, on March 26, 2021, the Butantan Institute announced it would seek to begin clinical trials. Mexico-based Avimex plans to create an intranasal spray version of the vaccine. In Thailand the Government Pharmaceutical Organization is conducting a trial in coordination with Mahidol University. [13] [14] Reflecting the freedom offered by the ease of the manufacturing process, Thai health minister Anutin Charnvirakul referred to the vaccine as "produced by Thai people for Thai people". [9]

Related Research Articles

Peter Hotez

Peter Jay Hotez is an American scientist, pediatrician, and advocate in the fields of global health, vaccinology, and neglected tropical disease control. He serves as founding dean of the National School of Tropical Medicine, Professor of Pediatrics and Molecular Virology & Microbiology at Baylor College of Medicine, where he is also Director of the Texas Children's Hospital Center for Vaccine Development and Texas Children's Hospital Endowed Chair in Tropical Pediatrics, and University Professor of Biology at Baylor University. Hotez served previously as president of the American Society of Tropical Medicine and Hygiene and is a founding Editor-in-Chief of PLOS Neglected Tropical Diseases. He is also the co-director of Parasites Without Borders, a global nonprofit organization with a focus on those suffering from parasitic diseases in subtropical environments.

COVID-19 vaccine Vaccine designed to provide acquired immunity against SARS-CoV-2

A COVID‑19 vaccine is a vaccine intended to provide acquired immunity against severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2), the virus that causes coronavirus disease 2019 (COVID‑19). Prior to the COVID‑19 pandemic, an established body of knowledge existed about the structure and function of coronaviruses causing diseases like severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS). This knowledge accelerated the development of various vaccine platforms during early 2020. The initial focus of SARS-CoV-2 vaccines was on preventing symptomatic, often severe illness. On 10 January 2020, the SARS-CoV-2 genetic sequence data was shared through GISAID, and by 19 March, the global pharmaceutical industry announced a major commitment to address COVID-19. The COVID‑19 vaccines are widely credited for their role in reducing the spread, severity, and death caused by COVID-19.

CoronaVac Vaccine against COVID-19

CoronaVac, also known as the Sinovac COVID-19 vaccine, is an inactivated virus COVID-19 vaccine developed by the Chinese company Sinovac Biotech. It was Phase III clinical trialled in Brazil, Chile, Indonesia, the Philippines, and Turkey and relies on traditional technology similar to BBIBP-CorV and Covaxin, other inactivated-virus COVID-19 vaccines. CoronaVac does not need to be frozen and both the final product and the raw material for formulating CoronaVac can be transported refrigerated at 2–8 °C (36–46 °F), temperatures at which flu vaccines are kept.

ZF2001 Vaccine against COVID-19

ZF2001, trade-named ZIFIVAX or ZF-UZ-VAC-2001, is an adjuvanted protein subunit COVID-19 vaccine developed by Anhui Zhifei Longcom in collaboration with the Institute of Microbiology at the Chinese Academy of Sciences. The vaccine candidate is in Phase III trials with 29,000 participants in China, Ecuador, Malaysia, Pakistan, and Uzbekistan.

CoVLP COVID-19 vaccine candidate produced in a plant

CoVLP is a COVID-19 vaccine candidate developed by Medicago and GlaxoSmithKline (GSK). It is a coronavirus virus-like particle vaccine grown in the Australian weed, Nicotiana benthamiana.

EpiVacCorona EpiVacCorona vaccine against COVID-19

EpiVacCorona is a peptide-based vaccine against COVID-19 developed by the VECTOR center of Virology. It consists of three chemically synthesized peptides that are conjugated to a large carrier protein. This protein is a fusion product of a viral nucleocapsid protein and a bacterial MBP protein. The third phase of a clinical trial, which should show whether the vaccine is able to protect people from COVID-19 or not, was launched in November 2020 with more than three thousand participants. The interim results of the Phase III study are expected to be announced in late 2021 or early 2022. According to the vaccine developers, the peptides and the viral part of the chimeric protein should immunize people who received this vaccine against SARS-CoV-2 and trigger the production of protective antibodies. However, some experts in the field have expressed concerns about the selection of peptides for use as vaccine antigens. In addition, there are also serious concerns about the vaccine immunogenicity data, which have fueled independent civic research efforts and criticism by some experts. Meanwhile, the EpiVacCorona has received vaccine emergency authorization in a form of government registration in Russia and is available for vaccination outside the clinical trials. The vaccine delivered via intramuscular route and aluminum hydroxide serves as an immunological adjuvant.

CureVac COVID-19 vaccine Vaccine candidate against COVID-19

The CureVac COVID-19 vaccine is a COVID-19 vaccine candidate developed by CureVac N.V. and the Coalition for Epidemic Preparedness Innovations (CEPI). The vaccine showed inadequate results in its Phase III trials with only 47% efficacy.

SCB-2019 Vaccine candidate against COVID-19

SCB-2019 is a protein subunit COVID-19 vaccine developed by Clover Biopharmaceuticals using an adjuvant from Dynavax technologies. Positive results of Phase I trials for the vaccine were published in The Lancet and the vaccine completed enrollment of 29,000 participants in Phase II/III trials in July 2021. In September 2021, SCB-2019 announced Phase III results showing 67% efficacy against all cases of COVID-19 and 79% efficacy against all cases of the Delta variant. Additionally, the vaccine was 84% effective against moderate cases and 100% effective against hospitalization.

QazCovid-in Vaccine candidate against COVID-19

QazCovid-in, commercially known as QazVac, is a COVID-19 vaccine developed by the Research Institute for Biological Safety Problems in Kazakhstan. QazCoVac-P is a second COVID-19 vaccine developed by the Kazakh Biosafety Research Institute and in clinical trials.

GRAd-COV2 Vaccine candidate against COVID-19

GRAd-COV2 is a COVID-19 vaccine candidate developed by ReiThera Srl and Lazzaro Spallanzani National Institute for Infectious Diseases. It is based on a novel replication defective Gorilla Adenovirus and encodes for SARS-COV-2 full length prefusion stabilized Spike protein. More specifically, the vector used is the simian group C adenovirus GRAd32, isolated from a captive gorilla, with a genome deleted of the entire E1 and E3 regions and the native E4 region replaced with the E4 orf6 of human adenovirus 5 (hAd5).

Viral vector vaccine Type of vaccine

A viral vector vaccine is a vaccine that uses a viral vector to deliver genetic material coding for a desired antigen into the recipient's host cells. As of April 2021, six viral vector vaccines have been authorized for use in human at least one country: four COVID-19 vaccines and two Ebola vaccines.

Chinese Academy of Medical Sciences COVID-19 vaccine Vaccine against COVID-19

Chinese Academy of Medical Sciences COVID-19 vaccine, or IMBCAMS COVID-19 vaccine, traded as Covidful, is a COVID-19 vaccine developed by Institute of Medical Biology, Chinese Academy of Medical Sciences.

Minhai COVID-19 vaccine Vaccine against COVID-19

Minhai COVID-19 vaccine, trademarked as KCONVAC, is a COVID-19 vaccine developed by Shenzhen Kangtai Biological Products Co. Ltd and its subsidiary, Beijing Minhai Biotechnology Co., Ltd.

West China Hospital COVID-19 vaccine Vaccine candidate against COVID-19

West China Hospital COVID-19 vaccine is a COVID-19 vaccine candidate developed by Jiangsu Province Centers for Disease Control and Prevention, West China Hospital and Sichuan University.

TurkoVac Vaccine candidate against COVID-19

TURKOVAC is a COVID-19 vaccine candidate developed by Health Institutes of Turkey and Erciyes University.

EuCorVac-19 is a COVID-19 vaccine candidate developed by EuBiologics Co.

GX-19 Vaccine candidate against COVID-19

GX-19 is a COVID-19 vaccine candidate developed by Genexine consortium.

COVID-19 vaccination in Thailand

COVID-19 vaccination in Thailand is an ongoing mass immunization in response to the ongoing pandemic in the country.

GBP510 Vaccine candidate against COVID-19

GBP510 is a COVID-19 vaccine candidate developed by SK Bioscience and GSK.

COVID-19 vaccine clinical research

COVID-19 vaccine clinical research is the clinical research on COVID-19 vaccines, including their efficacy, effectiveness and safety. There are 22 vaccines authorized for use by national governments, with six vaccines being approved for emergency or full use by at least one WHO-recognised stringent regulatory authority; and five of them are in Phase IV. 204 vaccines under clinical trials that have not yet been authorized. There are also nine clinical trials on heterologous vaccination courses.

References

  1. "Study of a Live rNDV Based Vaccine Against COVID-19". ClinicalTrials.gov. United States National Library of Medicine. 4 May 2021. NCT04871737. Retrieved 4 May 2021.
  2. "Butantan vai desenvolver e produzir nova vacina contra a Covid-19; testes clínicos da ButanVac devem começar em abril".
  3. Simões E, Fonseca P (26 March 2021). "Brazil posts record 3,650 new COVID-19 deaths, unveils two homegrown vaccines". Reuters. Retrieved 7 April 2021. Earlier, Sao Paulo's Butantan biomedical institute said it will seek approval ... Butantan aims to produce 40 million doses of the Butanvac vaccine ... The vaccine was developed using a modified virus, which causes the Newcastle disease in birds ...
  4. "Clinical Trial of the COVID-19 Vaccine (Recombinant, Inactivated) in Brazil (ADAPTCOV)". clinicaltrials.gov. United States National Library of Medicine. 6 August 2021. Retrieved 6 August 2021.
  5. "A Phase 1/2 Safety and Immunogenicity Trial of COVID-19 Vaccine COVIVAC". clinicaltrials.gov. United States National Library of Medicine. April 2021. Retrieved 9 April 2021.
  6. "Mahidol-GPO's human trials of its COVID-19 vaccine show promising results". Thai PBS World. 1 July 2021. Retrieved 19 July 2021.
  7. Juarez, Carlos (22 April 2021). "Vacuna Patria: esto es lo que se sabe de su avance y eventual producción". The Logistics World. Retrieved 24 June 2021.
  8. Cross R (20 July 2020). "What will it take to make an effective vaccine for COVID-19?". Chemical & Engineering News . 98 (28): 35–42. doi: 10.1021/cen-09828-cover .
  9. 1 2 3 4 Zimmer C (5 April 2021). "Researchers Are Hatching a Low-Cost Coronavirus Vaccine". The New York Times . Retrieved 7 April 2021.
  10. 1 2 Airhart M (5 April 2021). "Human Trials Begin for a Low-Cost COVID-19 Vaccine to Extend Global Access". University of Texas. Retrieved 7 April 2021.
  11. Sun W, Leist SR, McCroskery S, Liu Y, Slamanig S, Oliva J, et al. (2020). "Newcastle disease virus (NDV) expressing the spike protein of SARS-CoV-2 as vaccine candidate". EBioMedicine. 62: 103132. doi:10.1016/j.ebiom.2020.103132. PMC   7679520 . PMID   33232870.
  12. Hsieh CL, Goldsmith JA, Schaub JM, DiVenere AM, Kuo HC, Javanmardi K, et al. (September 2020). "Structure-based design of prefusion-stabilized SARS-CoV-2 spikes". Science. 369 (6510): 1501–1505. Bibcode:2020Sci...369.1501H. doi:10.1126/science.abd0826. PMC   7402631 . PMID   32703906.
  13. Clinical trial number NCT04764422 for "Assess the Safety and Immunogenicity of NDV-HXP-S Vaccine in Thailand" at ClinicalTrials.gov
  14. Wipatayotin A (11 February 2021). "Thai-made vaccine ready 'by next year'". Bangkok Post. Bangkok Post Public Company Limited. Retrieved 9 April 2021.